Analysts Have Conflicting Sentiments on These Healthcare Companies: Pacira Pharmaceuticals (PCRX), Galmed Pharmaceuticals (GLMD) and Rani Therapeutics Holdings (RANI)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pacira Pharmaceuticals (PCRX – Research Report), Galmed Pharmaceuticals (GLMD – Research Report) and Rani Therapeutics Holdings (RANI – Research Report).

Pacira Pharmaceuticals (PCRX)

Needham analyst Serge Belanger maintained a Buy rating on Pacira Pharmaceuticals today and set a price target of $63.00. The company’s shares closed last Thursday at $38.50, close to its 52-week low of $37.69.

According to TipRanks.com, Belanger is a 2-star analyst with an average return of -0.1% and a 41.8% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, KalVista Pharmaceuticals, and Collegium Pharmaceutical.

Pacira Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $67.88, implying a 77.2% upside from current levels. In a report issued on January 4, Jefferies also maintained a Buy rating on the stock with a $54.00 price target.

See today’s best-performing stocks on TipRanks >>

Galmed Pharmaceuticals (GLMD)

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Galmed Pharmaceuticals today. The company’s shares closed last Thursday at $0.80.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 13.2% and a 39.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Madrigal Pharmaceuticals, and Aurinia Pharmaceuticals.

Galmed Pharmaceuticals has an analyst consensus of Hold.

Rani Therapeutics Holdings (RANI)

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Rani Therapeutics Holdings today and set a price target of $22.00. The company’s shares closed last Thursday at $6.66, close to its 52-week low of $5.11.

According to TipRanks.com, Kapoor is a 3-star analyst with an average return of 4.9% and a 40.9% success rate. Kapoor covers the Healthcare sector, focusing on stocks such as Century Therapeutics, CytomX Therapeutics, and Lyell Immunopharma.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Rani Therapeutics Holdings with a $20.25 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on PCRX:

• Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million
• Pacira price target lowered to $50 from $54 at Cowen
• Pacira sinks after continuing to not provide outlook with monthly sales
• Pacira reports preliminary net product sales of $57.5M for November
• Paulson adds Rumble, exits Occidental in Q3